# A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

> **NCT03583697** · PHASE2 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 75 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** BMN 111
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03583697
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-13
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-01-26
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583697, "A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03583697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*